Jane Doe

And so it was during his tenure that the company came out with Wegovy around 2021, the same drug, but specifically for weight loss.

And that was really like the first significant anti-obesity drug to come out in a long time.

And that was really like the first significant anti-obesity drug to come out in a long time.

And that was really like the first significant anti-obesity drug to come out in a long time.

So Eli Lilly is their biggest rival, and the companies have spent years going back and forth trying to outdo each other. And Eli Lilly also has a similar past in the sense that they were essentially the earliest supplier of insulin in the U.S. 100 years ago, and that remains a big part of their business. But where the competition really ratcheted up was the discovery of these GLP-1 drugs.

So Eli Lilly is their biggest rival, and the companies have spent years going back and forth trying to outdo each other. And Eli Lilly also has a similar past in the sense that they were essentially the earliest supplier of insulin in the U.S. 100 years ago, and that remains a big part of their business. But where the competition really ratcheted up was the discovery of these GLP-1 drugs.

So Eli Lilly is their biggest rival, and the companies have spent years going back and forth trying to outdo each other. And Eli Lilly also has a similar past in the sense that they were essentially the earliest supplier of insulin in the U.S. 100 years ago, and that remains a big part of their business. But where the competition really ratcheted up was the discovery of these GLP-1 drugs.

Post-ozempic, what that looked like was Lilly trying to really speed things up to get their answer out there, to try to find something even better. And their answer was not just to come out with another GLP-1 drug, but to come out with one that has a more powerful effect.

Post-ozempic, what that looked like was Lilly trying to really speed things up to get their answer out there, to try to find something even better. And their answer was not just to come out with another GLP-1 drug, but to come out with one that has a more powerful effect.

Post-ozempic, what that looked like was Lilly trying to really speed things up to get their answer out there, to try to find something even better. And their answer was not just to come out with another GLP-1 drug, but to come out with one that has a more powerful effect.

That while Ozempic was the gorilla of GLP-1s, that what Eli Lilly is doing is the King Kong of GLP-1s.

That while Ozempic was the gorilla of GLP-1s, that what Eli Lilly is doing is the King Kong of GLP-1s.

That while Ozempic was the gorilla of GLP-1s, that what Eli Lilly is doing is the King Kong of GLP-1s.

Eli Lilly's drug, Zepbound, has been shown in studies to help people lose more weight than Wegovy. So we're talking between 20 to 25 percent of someone's body weight compared with, you know, 15 to 20 percent for Wegovy. And so that's been Eli Lilly going out there and saying, Novo, that's great what you did, but we think we have something better.

Eli Lilly's drug, Zepbound, has been shown in studies to help people lose more weight than Wegovy. So we're talking between 20 to 25 percent of someone's body weight compared with, you know, 15 to 20 percent for Wegovy. And so that's been Eli Lilly going out there and saying, Novo, that's great what you did, but we think we have something better.

Eli Lilly's drug, Zepbound, has been shown in studies to help people lose more weight than Wegovy. So we're talking between 20 to 25 percent of someone's body weight compared with, you know, 15 to 20 percent for Wegovy. And so that's been Eli Lilly going out there and saying, Novo, that's great what you did, but we think we have something better.

Novo Nordisk has been developing its own combination drug that they call Kagrosima. And this was something that Novo Nordisk itself, as well as investors, were really counting on.

Novo Nordisk has been developing its own combination drug that they call Kagrosima. And this was something that Novo Nordisk itself, as well as investors, were really counting on.

Novo Nordisk has been developing its own combination drug that they call Kagrosima. And this was something that Novo Nordisk itself, as well as investors, were really counting on.

And so Novo Nordisk had set this expectation that this potential new drug could help people lose 25% of their body weight, which would be a higher bar than what ZepBound has shown for the most part.